And looking at the big picture,
once that study is completed,
and let's say you're happy with the results,
you have a signature that is promising,
what would be the next step in the vaccine 
development?
Where would this research fit in?
So obviously the next step would depend on 
whether the vaccine works or not.
Right now, I'm not at liberty to speak about that.
But if say, if we're talking about the vaccine 
does work
and it goes into clinical trials,
then it could be that in clinical trials,
you can draw blood from these patients
and profile them through cytometry or flow 
cytometry ideally,
because you would hope that you can shrink it 
down to 10 markers versus 37.
So profile all of those patients who do get your 
vaccination
and see if they have a signature,
which should help you understand without 
giving a challenge.
Is this vaccine protective?
